Hoya introduces Sensity, light reactive lenses

Article

Hoya recently introduced its new photochromic lenses, Hoya Sensity featuring Stabilight Technology, which the company says helps the lenses perform consistently in different climates and seasons.

Uithoorn, Netherlands-Hoya recently introduced its new photochromic lenses, Hoya Sensity featuring Stabilight Technology, which the company says helps the lenses perform consistently in different climates and seasons.

Hoya says the Hoya Sensity lens darkens up to 45 percent in 90 seconds, but the lens also fade back to full clarity quickly, lightening up to 23 percent after one minute, all while maintaining UV protection.

The company says the lenses are made using its Photochromic Precision Technology, a “microscopically accurate spin coating process tailored to freeform lens production” which ensures an even distribution of molecules over the entire lens surface.

Hoya Sensity can be supplied in all Hoya single vision, bifocal, and progressive lens designs. It can also be combined with Hoya premium coatings and comes in several stock options. The lenses are available in Bronze Brown and Silver Grey. 

Next: Adlens presents Adlens Sundials

DrFirst, My Vision Express partner to deliver comprehensive e-Rx to ECPs

Avellino launches DNA test for LASIK safety

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.